Sunmax Biotechnology Co., Ltd.
Research Sunmax Biotechnology Co., Ltd. (4728.TWO) on Bullrun: market cap TWD 21.51B, P/E 26.5, dividend yield 3.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4728.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 21.51B
- P/E26.5
- Dividend yield3.1%
- Financial periodQ2 2026
- RevenueTWD 618.26M
- Net incomeTWD 242.42M
- Free cash flowTWD 264.85M
- Gross margin81.9%
Valuation Snapshot
latest market cap is TWD 21.51B; P/E is 26.5; dividend yield is 3.1%.
Peer valuation comparison
Latest P/E is 26.55x versus a Healthcare sector median of 21.8x (21.8% above).
Latest dividend yield is 3.12% versus a Healthcare sector median of 2.4% (30.0% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 21.51B | 26.5 | 3.1% | 12.1 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 12.1 TWD, yield 3.1%.
About Sunmax Biotechnology Co., Ltd.
Sunmax Biotechnology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of biomedical-grade collagen and related products in Taiwan, Mainland China, and internationally. It offers collagen dermal filler sets, such as Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO injectable collagen gel with lidocaine. The company was founded in 2001 and is based in Tainan City, Taiwan.
ETFs that hold Sunmax Biotechnology Co., Ltd.
US-listed ETFs
Sunmax Biotechnology Co., Ltd. is held by 10 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
| Avantis Emerging Markets Ex-China Equity ETF (AVXC) | <0.01% | 0.33% |
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.04% | 0.65% |
| Dimensional Emerging Markets ex China Core Equity ETF (DEXC) | <0.01% | 0.43% |
| Dimensional Emerging Markets Sustainability Core 1 ETF (DFSE) | <0.01% | 0.41% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sunmax Biotechnology Co., Ltd.'s market cap?
Sunmax Biotechnology Co., Ltd.'s market capitalization is TWD 21.51B.
What is Sunmax Biotechnology Co., Ltd.'s P/E ratio?
Sunmax Biotechnology Co., Ltd.'s price-to-earnings (P/E) ratio is 26.5.
Does Sunmax Biotechnology Co., Ltd. pay a dividend?
Sunmax Biotechnology Co., Ltd. has a dividend yield of 3.1%.
What does Sunmax Biotechnology Co., Ltd. do?
Sunmax Biotechnology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of biomedical-grade collagen and related products in Taiwan, Mainland China, and internationally. It offers collagen dermal filler sets, such as Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO injectable collagen gel with lidocaine. The company was founded in 2001 and is based in Tainan City, Taiwan.